Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission

Tyagi, Komal; Mandal, Supratim; Roy, Adhiraj

doi:10.1016/j.bbcan.2021.188563

Cited by 39 publications

(28 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolites of the glycolysis pathway are abnormally activated in malignant tumours even under normoxia (called the Warburg effect) and promote the progression of cancers (63), including gallbladder cancer (64), pancreatic cancer (65), cervical cancer (66) and ovarian cancer (67). HIF-1a, as a transcription factor, can regulate metabolism-associated genes, which contribute to Warburg effect (68,69).…”

Section: Hif-1a Promotes the Glycolysis Pathway In Ovarian Cancermentioning

confidence: 99%

HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Ovarian cancer is the eighth most commonly diagnosed cancer among women worldwide. Even with the development of novel drugs, nearly one-half of the patients with ovarian cancer die within five years of diagnosis. These situations indicate the need for novel therapeutic agents for ovarian cancer. Increasing evidence has shown that hypoxia-inducible factor-1α(HIF-1α) plays an important role in promoting malignant cell chemoresistance, tumour metastasis, angiogenesis, immunosuppression and intercellular interactions. The unique microenvironment, crosstalk and/or interaction between cells and other characteristics of ovarian cancer can influence therapeutic efficiency or promote the disease progression. Inhibition of the expression or activity of HIF-1α can directly or indirectly enhance the therapeutic responsiveness of tumour cells. Therefore, it is reasonable to consider HIF-1α as a potential therapeutic target for ovarian cancer. In this paper, we summarize the latest research on the role of HIF-1α and molecules which can inhibit HIF-1α expression directly or indirectly in ovarian cancer, and drug clinical trials about the HIF-1α inhibitors in ovarian cancer or other solid malignant tumours.

show abstract

Section: Hif-1a Promotes the Glycolysis Pathway In Ovarian Cancermentioning

confidence: 99%

HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The corresponding clinical information was downloaded from the TCGA-OV dataset ( https://portal.gdc.cancer.gov/ ). The mRNAsi indices of 273 SOC samples in TCGA were obtained from a previous study [ 4 ]. Perl language ( https://www.perl.org/ ) was used to convert gene IDs to gene symbols.…”

Section: Methodsmentioning

confidence: 99%

“…The subpopulation of cells has persistently maintained the competence of self-perpetuation and simultaneously given rise to differentiated types of progeny tumor cells through asymmetrical division [ 2 ]. The stemness of CSCs is an important cause of tumor chemoresistance as well as a potential target of anticancer strategies [ 3 , 4 ]. Investigating stemness-associated genes in advanced SOC might be feasible to explore drug response indicators [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tumorigenesis is considered an energy metabolic disease. Compared with metabolism of healthy and neoplastic cells, researchers found the oxidative phosphorylation pathway is dominant to provide ATP in normal cells, while the glycolytic pathway is the primary energy supply in tumor cells ( Nakagawa et al, 2020 ; Tyagi et al, 2021 ). Even in the presence of sufficient oxygen, the glycolytic pathway, an alteration known as the Warburg effect, or aerobic glycolysis, accounts for over 95% of energy supply ( Sun et al, 2018 ; Harris and Fenton 2019 ; Lu 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Noncoding RNAs in the Glycolysis of Ovarian Cancer

Zhang

Liu

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Energy metabolism reprogramming is the characteristic feature of tumors. The tumorigenesis, metastasis, and drug resistance of ovarian cancer (OC) is dependent on energy metabolism. Even under adequate oxygen conditions, OC cells tend to convert glucose to lactate, and glycolysis can rapidly produce ATP to meet their metabolic energy needs. Non-coding RNAs (ncRNAs) interact directly with DNA, RNA, and proteins to function as an essential regulatory in gene expression and tumor pathology. Studies have shown that ncRNAs regulate the process of glycolysis by interacting with the predominant glycolysis enzyme and cellular signaling pathway, participating in tumorigenesis and progression. This review summarizes the mechanism of ncRNAs regulation in glycolysis in OC and investigates potential therapeutic targets.

show abstract

Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission

Cited by 39 publications

References 97 publications

HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies

HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies

Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer

Noncoding RNAs in the Glycolysis of Ovarian Cancer

Contact Info

Product

Resources

About